SeqLL Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $13.4563
- Today's High:
- $14.99
- Open Price:
- $14.99
- 52W Low:
- $9.2
- 52W High:
- $86.4
- Prev. Close:
- $14.74
- Volume:
- 22889
Company Statistics
- Market Cap.:
- $6.21 million
- Book Value:
- 0.21
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $77969
- Profit Margin:
- 0%
- Return on Assets TTM:
- -40%
- Return on Equity TTM:
- -113.72%
Company Profile
SeqLL Inc had its IPO on 2021-08-27 under the ticker symbol SQL.
The company operates in the Healthcare sector and Diagnostics & Research industry. SeqLL Inc has a staff strength of 7 employees.
Stock update
Shares of SeqLL Inc opened at $14.99 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $13.46 - $14.99, and closed at $14.
This is a -5.02% slip from the previous day's closing price.
A total volume of 22,889 shares were traded at the close of the day’s session.
In the last one week, shares of SeqLL Inc have slipped by -21.79%.
SeqLL Inc's Key Ratios
SeqLL Inc has a market cap of $6.21 million, indicating a price to book ratio of 0.9701 and a price to sales ratio of 37.723.
In the last 12-months SeqLL Inc’s revenue was $0 with a gross profit of $77969 and an EBITDA of $-5240696. The EBITDA ratio measures SeqLL Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, SeqLL Inc’s operating margin was 0% while its return on assets stood at -40% with a return of equity of -113.72%.
In Q2, SeqLL Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
SeqLL Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-25.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into SeqLL Inc’s profitability.
SeqLL Inc stock is trading at a EV to sales ratio of 1143.1249 and a EV to EBITDA ratio of -0.3295. Its price to sales ratio in the trailing 12-months stood at 37.723.
SeqLL Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $6.68 million
- Total Liabilities
- $956705.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $99
- Dividend Payout Ratio
- 0%
SeqLL Inc ended 2024 with $6.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $6.68 million while shareholder equity stood at $2.91 million.
SeqLL Inc ended 2024 with $0 in deferred long-term liabilities, $956705.00 in other current liabilities, 139.00 in common stock, $-21627164.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.79 million and cash and short-term investments were $4.79 million. The company’s total short-term debt was $220,292 while long-term debt stood at $1.38 million.
SeqLL Inc’s total current assets stands at $4.82 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $2723.00 compared to accounts payable of $381842.00 and inventory worth $0.00.
In 2024, SeqLL Inc's operating cash flow was $0 while its capital expenditure stood at $99.
Comparatively, SeqLL Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $14
- 52-Week High
- $86.4
- 52-Week Low
- $9.2
- Analyst Target Price
- $3
SeqLL Inc stock is currently trading at $14 per share. It touched a 52-week high of $86.4 and a 52-week low of $86.4. Analysts tracking the stock have a 12-month average target price of $3.
Its 50-day moving average was $15.13 and 200-day moving average was $18.04 The short ratio stood at 1 indicating a short percent outstanding of 0%.
Around 3149.7% of the company’s stock are held by insiders while 731.2% are held by institutions.
Frequently Asked Questions About SeqLL Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company’s True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice’s Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.